Since the December 2016 Board meeting, one decision has been circulated to the Board electronically for approval by unanimous consent in line with Article 2.7.3.1 of the By-Laws.

On 13 March 2017, Board members were invited to consider the following:

The Gavi Alliance Board:

(a) **Approved** that the transitioned countries who have already been approved for an HPV National introduction (i.e. Bolivia, Guyana, Honduras and Sri Lanka) can apply for support for multi-age cohort HPV vaccinations (9-14 years of age) in year one of introduction of the vaccine, including support for 50% of vaccine costs for the additional cohorts as well as operational costs of US$ 0.45 per girl targeted.

(b) **Noted** that the funding associated with the above approval for the period 2017-2020 is expected to be approximately US$ 3 million and will be allotted to individual programmes from the Programme Funding Envelope approved by the Board for each year, in accordance with the Programme Funding Policy.

On 22 March 2017, consent to the decision had been received from all voting members of the Board and it was therefore considered approved by unanimous consent, and Board members informed accordingly.

In line with the Gavi Conflict of Interest Policy, Dr Yolani Batres (Honduras) recused herself from voting on the decision. Her Alternate Board member, Dr Sergey Khachatryan (Armenia) voted on behalf of their constituency.